What Are Industry Professionals Saying about Diabetes Complications?

LONDON - Aug. 15, 2013 - PRLog -- SMi's 11th annual installment in the Diabetes series is now around the corner and will host a line up of leading industry experts at the heart of Diabetes innovation.

Confirmed participants include Novo Nordisk, Astra Zeneca, Medicines Assessment, Roche, International Diabetes Federation and MSD. 

Phil Ambery, Medical Director, Cardiovascular and Metabolic R&D at GSK, who will be addressing delegates on therapeutic targets to reduce diseases in type 2 diabetes, commented:

"This conference is an excellent one stop shop to up-skill on current issues in diabetes therapy. I’m happy to chair what will no doubt be a very stimulating session”.

Natalia Borinshtyen, Head of Portfolio Strategy within the Global Diabetes Division at SANOFI, who will be leading a panel discussion on Microvascular complications stated:

"I am honoured to be invited to lead a panel discussion on Diabetes complications at Diabetes meeting in London. Development of disease modification therapy to prevent or treat complications is an important goal for the industry and academia and I am looking forward to an active discussion"

For further details on the Diabetes Conference visit:

http://www.smi-online.co.uk/goto/2013diabetes-conference65.asp

Diabetes: Secondary Complications, Regulation and Innovation
01 - 02 October 2013, London UK